Post-ischemic intravenous BDNF treatment improves functional motor recovery after thrombotic stroke (74)
Novo is continuing to bolster its obesity portfolio, recently inking a $2.1 billion collaboration with biotech Vivtex to develop next-generation oral obesity pills as part of a push from injectables to more convenient formulations
What the remaining readouts change is the breadth of the label, not whether Lilly can file
Hypoglycemia represents another potential risk, primarily in patients taking tirzepatide in combination with insulin or sulfonylureas
The study confirmed these drugs reduce risks of heart attacks, strokes, and other cardiovascular events
Major payers including Aetna, Cigna, Elevance Health, Humana, UnitedHealthcare and Wellcare also released their MA offerings for 2025, as previously reported by Fierce Healthcare